Sex, age, race and intervention type in clinical studies of HIV cure: A systematic review

AIDS Research and Human Retroviruses

Volumn 31, Issue 1, 2015, Pages 85-97

  Johnston, Rowena E ^a   Heitzeg, Mary M ^b  

^a Foundation for AIDS Research   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; D DIMER;

AGE; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; DEMOGRAPHY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; PRIORITY JOURNAL; RACE; RACE DIFFERENCE; SEX; SEX DIFFERENCE; SYSTEMATIC REVIEW; UNITED STATES; X CHROMOSOME; AGED; AGEISM; ANCESTRY GROUP; CLINICAL TRIAL (TOPIC); FEMALE; HIV INFECTIONS; MALE; MEDICAL RESEARCH; METHODOLOGY; PATIENT SELECTION; PROCEDURES; RACISM; SEXISM; VIROLOGY;

AGE FACTORS; AGED; AGEISM; ANTI-HIV AGENTS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CONTINENTAL POPULATION GROUPS; FEMALE; HIV INFECTIONS; HUMANS; MALE; PATIENT SELECTION; RACISM; RESEARCH DESIGN; SEX FACTORS; SEXISM;

EID: 84937111644     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0205     Document Type: Article

References (131)

1. Hutter G, Nowak D, Mossner M, et al.: Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med 2009;360(7):692-698
2. Sterling TR, Vlahov D, Astemborski J, et al.: Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001;344(10):720-725
3. Napravnik S, Poole C, Thomas JC, et al.: Gender difference in HIV RNA levels: A meta-analysis of published studies. J Acquir Immune Defic Syndr 2002;31(1):11-19
4. Farzadegan H, Hoover DR, Astemborski J, et al.: Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998;352(9139):1510-1514
5. Gandhi M, Bacchetti P, Miotti P, et al.: Does patient sex affect human immunodeficiency virus levels?. Clin Infect Dis 2002;35(3):313-322
6. Meditz AL, MaWhinney S, Allshouse A, et al.: Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis 2011;203(4):442-451
7. Delmas MC, Jadand C, De Vincenzi I, et al.: Gender difference in CD4 + cell counts persist after HIV-1 infection. SEROCO Study Group. AIDS 1997;11(8):1071-1073
8. Prins M, Robertson JR, Brettle RP, et al.: Do gender differences in CD4 cell counts matter?. AIDS 1999;13(17): 2361-2364
9. Currier JS, Spino C, Grimes J, et al.: Differences between women and men in adverse events and CD4 + responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000;24(4):316-324
10. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al.: Sex differences in nevirapine rash. Clin Infect Dis 2001;32(1): 124-129
11. Nicastri E, Leone S, Angeletti C, et al.: Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: A systematic review. J Antimicrob Chemother 2007;60(4):724-732
12. Hodder S, Arasteh K, De Wet J, et al.: Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med 2012;13(7):406-415
13. Barber TJ, Geretti AM, Anderson J, et al.: Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther 2011;16(6):805-814
14. Murri R, Lepri AC, Phillips AN, et al.: Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: Evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr 2003;34(2):184-190
15. Currier J, Averitt Bridge D, Hagins D, et al.: Sex-based outcomes of darunavir-ritonavir therapy: A single-group trial. Ann Intern Med 2010;153(6):349-357
16. Moore AL, Mocroft A, Madge S, et al.: Gender differences in virologic response to treatment in an HIV-positive population: A cohort study. J Acquir Immune Defic Syndr 2001;26(2):159-163
17. Mazhude C, Jones S, Murad S, et al.: Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 2002;16(11): 1566-1568
18. Gandhi M, Aweeka F, Greenblatt RM, et al.: Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004;44:499-523
19. Siddiqui RA, Sauermann U, Altmuller J, et al.: X chromosomal variation is associated with slow progression to AIDS in HIV-1-infected women. Am J Hum Genet 2009; 85(2):228-239
20. Borges AH, OConnor JL, Phillips AN, et al.: Factors associated with D-dimer levels in HIV-infected individuals. PLoS One 2014;9(3):e90978
21. Meier A, Chang JJ, Chan ES, et al.: Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009;15(8):955-959
22. Sajadi MM, Guan Y, DeVico AL, et al.: Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr 2011;57(1):9-15
23. Seillet C, Laffont S, Tremollieres F, et al.: The TLRmediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor alpha signaling. Blood 2012;119(2): 454-464
24. Chang JJ, Woods M, Lindsay RJ, et al.: Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J Infect Dis 2013;208(5):830-838
25. Fitch KV, Srinivasa S, Abbara S, et al.: Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013;208(11):1737-1746
26. Jantaratnotai N, Utaisincharoen P, Sanvarinda P, et al.: Phytoestrogens mediated anti-inflammatory effect through suppression of IRF-1 and pSTAT1 expressions in lipopolysaccharide-activated microglia. Int Immunopharmacol 2013;17(2):483-488
27. Weinberg A, Enomoto L, Marcus R, et al.: Effect of menstrual cycle variation in female sex hormones on cellular immunity and regulation. J Reprod Immunol 2011; 89(1):70-77
28. Lee YW, Eum SY, Nath A, and Toborek M: Estrogenmediated protection against HIV Tat protein-induced inflammatory pathways in human vascular endothelial cells. Cardiovasc Res 2004;63(1):139-148
29. Asin SN, Heimberg AM, Eszterhas SK, et al.: Estradiol and progesterone regulate HIV type 1 replication in peripheral blood cells. AIDS Res Hum Retroviruses 2008; 24(5):701-716
30. Katagiri D, Hayashi H, Victoriano AF, et al.: Estrogen stimulates transcription of human immunodeficiency virus type 1 (HIV-1). Int Immunopharmacol 2006;6(2):170-181
31. Wilson ME, Allred KF, Bisotti AJ, et al.: Estradiol negatively regulates HIV-LTR promoter activity in glial cells. AIDS Res Hum Retroviruses 2006;22(4):350-356
32. Heron PM, Turchan-Cholewo J, Bruce-Keller AJ, et al.: Estrogen receptor alpha inhibits the estrogen-mediated suppression of HIV transcription in astrocytes: Implications for estrogen neuroprotection in HIV dementia. AIDS Res Hum Retroviruses 2009;25(11):1071-1081
33. Szotek EL, Narasipura SD, and Al-Harthi L: 17beta-Estradiol inhibits HIV-1 by inducing a complex formation between beta-catenin and estrogen receptor alpha on the HIV promoter to suppress HIV transcription. Virology 2013;443(2):375-383
34. Tasker C, Ding J, Schmolke M, et al.: 17beta-Estradiol protects primary macrophages against HIV infection through induction of interferon-alpha. Viral Immunol 2014; 27(4):140-150
35. Laurence J, Cooke H, and Sikder SK: Effect of tamoxifen on regulation of viral replication and human immunodeficiency virus (HIV) long terminal repeat-directed transcription in cells chronically infected with HIV-1. Blood 1990;75(3):696-703
36. Pinheiro I, Dejager L, and Libert C: X-chromosome-located microRNAs in immunity: Might they explain male/ female differences?. The X chromosome-genomic context may affect X-located miRNAs and downstream signaling, thereby contributing to the enhanced immune response of females. Bioessays 2011;33(11):791-802
37. Addo MM and Altfeld M: Sex-based differences in HIV type 1 pathogenesis. J Infect Dis 2014;209(Suppl 3):S86-S92
38. Tran TA, de Goer de Herve MG, Hendel-Chavez H, et al.: Resting regulatory CD4 T cells: A site of HIV persistence in patients on long-term effective antiretroviral therapy. PLoS One 2008;3(10):e3305
39. Arruvito L, Sanz M, Banham AH, et al.: Expansion of CD4 + CD25 + and FOXP3 + regulatory T cells during the follicular phase of the menstrual cycle: Implications for human reproduction. J Immunol 2007;178(4):2572-2578
40. Joshua TV, Rizzo JD, Zhang MJ, et al.: Access to hematopoietic stem cell transplantation: Effect of race and sex. Cancer 2010;116(14):3469-3476
41. Mehta P, Pollock BH, Nugent M, et al.: Access to stem cell transplantation: Do women fare as well as men?. Am J Hematol 2003;72(2):99-102
42. Grant M, Cooke L, Williams AC, et al.: Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: A comparison of sociodemographic, disease, and treatment characteristics. Support Care Cancer 2012;20(11):2697-2704
43. Gratwohl A, Stern M, Brand R, et al.: Risk score for outcome after allogeneic hematopoietic stem cell transplantation: A retrospective analysis. Cancer 2009;115(20): 4715-4726
44. Johny A, Song KW, Nantel SH, et al.: Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide. Biol Blood Marrow Transplant 2006;12(4):480-489
45. Deasy BM, Lu A, Tebbets JC, et al.: A role for cell sex in stem cell-mediated skeletal muscle regeneration: Female cells have higher muscle regeneration efficiency. J Cell Biol 2007;177(1):73-86
46. Yukl SA, Boritz E, Busch M, et al.: Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient. PLoS Pathog 2013; 9(5):e1003347
47. Chun TW, Justement JS, Murray D, et al.: Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: Implications for eradication. AIDS 2010;24(18):2803-2808
48. Jain V, Hartogensis W, Bacchetti P, et al.: Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013;208(8):1202-1211
49. Boulassel MR, Chomont N, Pai NP, et al.: CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. J Clin Virol 2012;53(1):29-32
50. Stengaard AR, Lazarus JV, Donoghoe MC, et al.: Access to highly active antiretroviral therapy (HAART) for women and children in the WHO European Region 2002-2006. AIDS Care 2009;21(7):893-902
51. WHO, UNICEF, UNAIDS: Global update on HIV treatment 2013: Results, impact and opportunities, 2013
52. CDC: HIV in the United States: The Stages of Care. www.cdc.gov/hiv/pdf/research-mmp-stagesofcare.pdf. Accessed July 14, 2014
53. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000; 355(9210):1131-1137
54. Nakagawa F: Factors associated with short-term changes in HIV viral load and CD4 + cell count in antiretroviralnaive individuals. AIDS 2014;28(9):1351-1356
55. Allers K, Bosel D, Epple HJ, et al.: Effect of age on the CD4( + ) T-cell impairment in HIV-infected persons without and with cART. J Acquir Immune Defic Syndr 2014; 66(1):7-15
56. Althoff KN, Justice AC, Gange SJ, et al.: Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010;24(16):2469-2479
57. Dumond JB, Adams JL, Prince HM, et al.: Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: A pilot study. HIV Med 2013;14(7): 401-409
58. Goodkin K, Shapshak P, Asthana D, et al.: Older age and plasma viral load in HIV-1 infection. AIDS 2004;18(Suppl 1): S87-98
59. Greig J, Casas EC, OBrien DP, et al.: Association between older age and adverse outcomes on antiretroviral therapy: A cohort analysis of programme data from nine countries. AIDS 2012;26(Suppl 1):S31-37
60. Kalayjian RC, Spritzler J, Matining RM, et al.: Older HIV-infected patients on antiretroviral therapy have Bcell expansion and attenuated CD4 cell increases with immune activation reduction. AIDS 2013;27(10):1563-1571
61. Sabin CA, Smith CJ, dArminio Monforte A, et al.: Response to combination antiretroviral therapy: Variation by age. AIDS 2008;22(12):1463-1473
62. Andrade RM, Hygino J, Kasahara TM, et al.: High IL-10 production by aged AIDS patients is related to high frequency of Tr-1 phenotype and low in vitro viral replication. Clin Immunol 2012;145(1):31-43
63. Deeks SG: HIV infection, inflammation, immunosenescence, and aging Annu Rev Med 2011;62:141-155
64. Dock JN and Effros RB: Role of CD8 T cell replicative senescence in human aging and in HIV-mediated immunosenescence. Aging Dis 2011;2(5):382-397
65. Hoffman RM, Jamieson BD, Bosch RJ, et al.: Baseline immune phenotypes and CD4 + T lymphocyte responses to antiretroviral therapy in younger versus older HIVinfected individuals. J Clin Immunol 2011;31(5):873-881
66. Tassiopoulos K, Landay A, Collier AC, et al.: CD28-negative CD4 + and CD8 + T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies. J Infect Dis 2012;205(11):1730-1738
67. Tenorio AR, Spritzler J, Martinson J, et al.: The effect of aging on T-regulatory cell frequency in HIV infection. Clin Immunol 2009;130(3):298-303
68. Gratwohl A, Hermans J, Goldman JM, et al.: Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352(9134):1087-1092
69. Sorror ML, Sandmaier BM, Storer BE, et al.: Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011; 306(17):1874-1883
70. Bogunia-Kubik K, Duda D, Suchnicki K, et al.: CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica 2006;91(12):1628-1634
71. Bogunia-Kubik K, Suchnicki K, and Lange A: HLADR11 in addition to donor age, gender, and major blood group incompatibility influence the incidence of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplant Proc 2003;35(4): 1556-1558
72. Imahashi N, Suzuki R, Fukuda T, et al.: Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. Bone Marrow Transplant 2013;48(1):56-62
73. Althoff KN, Gebo KA, Gange SJ, et al.: CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. AIDS Res Ther 2010;7:45
74. Mocroft A, Lundgren JD, Sabin ML, et al.: Risk factors and outcomes for late presentation for HIV-positive persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013;10(9):e1001510
75. Montlahuc C, Guiguet M, Abgrall S, et al.: Impact of late presentation on the risk of death among HIV-infected people in France (2003-2009). J Acquir Immune Defic Syndr 2013;64(2):197-203
76. Smith PR, Sarner L, Murphy M, et al.: Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4 +lymphocyte count in a cohort of HIV-1-infected individuals. J Clin Virol 2003;26(1):101-107
77. Anastos K, Gange SJ, Lau B, et al.: Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr 2000;24(3): 218-226
78. Easterbrook PJ, Farzadegan H, Hoover DR, et al.: Racial differences in rate of CD4 decline in HIV-1-infected homosexual men. AIDS 1996;10(10):1147-1155
79. Chikata T, Carlson JM, Tamura Y, et al.: Host-specific adaptation of HIV-1 subtype B in the Japanese population. J Virol 2014;88(9):4764-4775
80. Gartland AJ, Li S, McNevin J, et al.: Analysis of HLA A 02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial. J Virol 2014;88(15):8242-8255
81. Murphy K, Hoover DR, Shi Q, et al.: Association of selfreported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. AIDS 2013;27(15):2413-2423
82. Longo DM, Louie B, Mathi K, et al.: Racial differences in B cell receptor signaling pathway activation. J Transl Med 2012;10:113
83. Lucey DR, Hendrix CW, Andrzejewski C, et al.: Comparison by race of total serum IgG, IgA, and IgM with CD4 + T-cell counts in North American persons infected with the human immunodeficiency virus type 1. J Acquir Immune Defic Syndr 1992;5(4):325-332
84. Kalinkovich A, Borkow G, Weisman Z, et al.: Increased CCR5 and CXCR4 expression in Ethiopians living in Israel: Environmental and constitutive factors. Clin Immunol 2001;100(1):107-117
85. Koesters SA, Matu L, Kiama P, et al.: Elevation of immune activation in Kenyan women is associated with alterations in immune function: Implications for vaccine development. J Clin Immunol 2004;24(6):702-709
86. Messele T, Abdulkadir M, Fontanet AL, et al.: Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts. Clin Exp Immunol 1999;115(3):443-450
87. Kile DA, MaWhinney S, Aquilante CL, et al.: A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses 2012;28(10):1227-1234
88. Li J, Menard V, Benish RL, et al.: Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: Implications for HIV/AIDS treatment. Pharmacogenomics 2012;13(5):555-570
89. Ribaudo HJ, Liu H, Schwab M, et al.: Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS Clinical Trials Group study. J Infect Dis 2010;202(5): 717-722
90. de Maat MM, Nellen JF, Huitema AD, et al.: Race is not associated with nevirapine pharmacokinetics. Ther Drug Monit 2004;26(4):456-458
91. Stohr W, Back D, Dunn D, et al.: Factors influencing efavirenz and nevirapine plasma concentration: Effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13(5):675-685
92. Saag M, Balu R, Phillips E, et al.: High sensitivity of human leukocyte antigen-b 5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008;46(7):1111-1118
93. Orkin C, Sadiq ST, Rice L, et al.: Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B 5701 in HIV-1-infected UK subjects. HIV Med 2010;11(3):187-192
94. Rozenberg L, Haagmans BL, Neumann AU, et al.: Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. AIDS 2009;23(18):2439-2450
95. HIV gp120 vaccine-VaxGen: AIDSVAX, AIDSVAX B/ B, AIDSVAX B/E, HIV gp120 vaccine-Genentech, HIV gp120 vaccine AIDSVAX-VaxGen, HIV vaccine AIDSVAX-VaxGen. Drugs R D 2003;4(4):249-253
96. Mielcarek M, Gooley T, Martin PJ, et al.: Effects of race on survival after stem cell transplantation. Biol Blood Marrow Transplant 2005;11(3):231-239
97. Roeder C, Jordan S, Schulze Zur Wiesch J, et al.: Agerelated differences in response to peginterferon alfa-2a/ ribavirin in patients with chronic hepatitis C infection. World J Gastroenterol 2014;20(31):10984-10993
98. Malnick S, Maor Y, Melzer E, et al.: Chronic hepatitis C in the aged: Much ado about nothing or nothing to do?. Drugs Aging 2014;31(5):339-347
99. Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, et al.: Gender influence on treatment of chronic hepatitis C genotype 1. Rev Soc Bras Med Trop 2010;43(3):217-223
100. Giannelli V, Giusto M, Farcomeni A, et al.: Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. Transpl Int 2012;25(4): 448-454
101. Lawitz E, Mangia A, Wyles D, et al.: Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368(20):1878-1887
102. NIH: NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research, amended, October 2001. http://grants1.nih.gov/grants/ funding/women-min/guidelines-amended-10-2001.ht. Accessed June 26, 2014
103. Clayton JA and Collins FS: Policy: NIH to balance sex in cell and animal studies. Nature 2014;509(7500):282-283
104. CDC: Epidemiology of HIV Infection through 2011. www .cdc.gov/hiv/pdf/statistics-epidemiology-of-infection- through-2011.pdf. Accessed June 26, 2014
105. CDC: HIV Among Older Americans. www.cdc.gov/hiv/ risk/age/olderamericans/. Accessed June 26, 2014
106. UNAIDS: Women, Girls, Gender Equality and HIV. www .unaids.org/en/media/unaids/contentassets/documents/ factsheet/2012/20120217-FS-WomenGirls-en.pdf. Accessed June 26, 2014
107. UNAIDS: HIV and Aging: A special supplement to the UNAIDS report on the global AIDS epidemic 2013. www .unaids.org/en/media/unaids/contentassets/documents/ unaidspublication/2013/20131101-JC2563-hiv-and-aging-en.pdf. Accessed June 26, 2014
108. UNAIDS: Core Epidemiology Slides; September 2013. www.unaids.org/en/media/unaids/contentassets/documents/ epidemiology/2013/gr2013/201309-epi-core-en.pdf. Accessed June 26, 2014
109. Falcon R, Bridge DA, Currier J, et al.: Recruitment and retention of diverse populations in antiretroviral clinical trials: Practical applications from the gender, race and clinical experience study. J Womens Health (Larchmt) 2011;20(7):1043-1050
110. Desquilbet L, Goujard C, Rouzioux C, et al.: Does transient HAART during primary HIV-1 infection lower the virological set-point?. AIDS 2004;18(18):2361-2369
111. Hoen B, Fournier I, Lacabaratz C, et al.: Structured treatment interruptions in primary HIV-1 infection: The ANRS 100 PRIMSTOP trial. J Acquir Immune Defic Syndr 2005;40(3):307-316
112. McKellar MS, Cope AB, Gay CL, et al.: Acute HIV-1 infection in the Southeastern United States: A cohort study. AIDS Res Hum Retroviruses 2013;29(1):121-128
113. 2012 HIV/STD Surveillance Report: http://epi.publichealth .nc.gov/cd/stds/figures/std12rpt.pdf. Accessed September 9, 2014
114. Hecht FM: Personal communication. UCSF School of Medicine
115. San Francisco AIDS Foundation: http://sfaf.org/hiv-info/ statistics/. Accessed September 10, 2014
116. Sabundayo BP, McArthur JH, Langan SJ, et al.: High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection. Pharmacotherapy 2006;26(5): 674-681
117. Maryland Department of Health and Mental Hygiene: http://phpa.dhmh.maryland.gov/OIDEOR/CHSE/SitePages/ statistics.aspx. Accessed September 10, 2014
118. Krastinova E, Seng R, Yeni P, et al.: Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection?. The ANRS PRIMO and COPANA cohorts. PLoS One 2013;8(8):e71473
119. AVERT: www.avert.org/european-hiv-aids-statistics.htm. Accessed September 10, 2014
120. Fidler S, Porter K, Ewings F, et al.: Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013;368(3):207-217
121. Castillo-Mancilla JR, Cohn SE, Krishnan S, et al.: Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials. HIV Clin Trials 2014;15(1):14-26
122. Soon GG, Min M, Struble KA, et al.: Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). AIDS Patient Care STDS 2012;26(8):444-453
123. Manfredi R: HIV disease and advanced age: An increasing therapeutic challenge. Drugs Aging 2002;19(9):647-669
124. Dhalla S and Poole G: Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention. Hum Vaccin Immunother 2014;10(7
125. Byrd GS, Edwards CL, Kelkar VA, et al.: Recruiting intergenerational African American males for biomedical research Studies: A major research challenge. J Natl Med Assoc 2011;103(6):480-487
126. Metch B, Frank I, Novak R, et al.: Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials. AIDS Behav 2013; 17(2):760-772
127. Blackstock OJ, Beach MC, Korthuis PT, et al.: HIV providersperceptions of and attitudes toward female versus male patients. AIDS Patient Care STDS 2012;26(10): 582-588
128. van Ryn M, Burgess D, Malat J, et al.: Physicians perceptions of patients social and behavioral characteristics and race disparities in treatment recommendations for men with coronary artery disease. Am J Public Health 2006;96(2):351-357
129. Steward WT, Koester KA, Myers JJ, et al.: Provider fatalism reduces the likelihood of HIV-prevention counseling in primary care settings. AIDS Behav 2006;10(1):3-12
130. Martinson JJ, Chapman NH, Rees DC, et al.: Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997;16(1):100-103
131. Jakobsson M, Scholz SW, Scheet P, et al.: Genotype, haplotype and copy-number variation in worldwide human populations. Nature 2008;451(7181):998-1003